Scholar Rock director Akkaraju buys $12 million in shares

Srinivas Akkaraju, a director at Scholar Rock Holding Corp (NASDAQ:SRRK), acquired common stock totaling approximately $12 million through a series of transactions between October 23 and October 26, 2026. The purchases were executed at prices ranging from $41.31 to $41.82 per share.The insider buying comes as SRRK trades at $42.49, giving the biotech company a market capitalization of $5.08 billion. The stock has delivered a 42% return over the past year, though InvestingPro analysis indicates the shares are currently overvalued relative to its Fair Value estimate. Investors tracking valuation metrics can explore more opportunities on InvestingPro’s Most Overvalued stocks list.

The acquisitions were made indirectly through investment entities where Mr. Akkaraju maintains voting and investment power. On October 23, 2026, Samsara BioCapital, L.P. purchased 47,000 shares at a weighted average price of $41.31, while Samsara Opportunity Fund, L.P. acquired 94,000 shares at the same average price. Later that day, Samsara BioCapital, L.P. bought an additional 500 shares at a weighted average price of $41.82, and Samsara Opportunity Fund, L.P. acquired 1,000 shares at the same average price.

Further transactions occurred on October 26, 2026. Samsara BioCapital, L.P. purchased 48,988 shares at a weighted average price of $41.59, and Samsara Opportunity Fund, L.P. acquired 97,982 shares, also at an average price of $41.59.

Mr. Akkaraju is considered to beneficially own the securities held by Samsara BioCapital, L.P. and Samsara Opportunity Fund, L.P. due to his voting and investment authority over these entities. However, he disclaims beneficial ownership in these securities except to the extent of his pecuniary interest. The reported prices are weighted averages, reflecting multiple transactions within specific ranges. For example, shares acquired at the $41.31 average price were purchased between $40.77 and $41.75, while those at $41.82 averaged prices from $41.78 to $41.85, and shares at $41.59 averaged prices from $41.15 to $41.93.

The filing also noted a prior disposition of 83,585 shares by Samsara BioCapital LP, in which Mr. Akkaraju had no pecuniary interest. This specific disposition did not alter his beneficial ownership and was exempt from reporting under Section 16.Scholar Rock remains unprofitable with earnings per share of -$3.36 over the last twelve months. InvestingPro subscribers have access to 6 additional ProTips for SRRK, plus comprehensive Pro Research Reports covering over 1,400 US equities with expert analysis and actionable intelligence for smarter investment decisions.

In other recent news, Scholar Rock has been the focus of multiple analyst updates and strategic developments. Truist Securities reiterated its Buy rating on Scholar Rock, setting a price target of $77.00, following insights from a non-deal roadshow and feedback from key opinion leaders regarding the company’s Isembyld treatment for spinal muscular atrophy. The firm highlighted the potential uptake of Isembyld, with expectations that 50-60% of SMA patients might be on the drug within five years. Additionally, Truist raised its price target due to updated drug pricing, now set at $11,659 per 150-mg vial.

Raymond James also maintained a Strong Buy rating with a $72.00 price target after Scholar Rock resubmitted its Marketing Authorization Application for apitegromab in the European Union. This resubmission is a significant step as the company anticipates a Committee for Medicinal Products for Human Use opinion in the first half of 2027. Piper Sandler reiterated an Overweight rating with a $75.00 price target, noting the divided opinions among physicians regarding Isembyld’s fracture risk warning. These recent developments reflect the ongoing interest and confidence in Scholar Rock’s strategic direction and product potential.